AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02995694
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol Vaginal Cream
Trial: NCT02995694
Drug: Reference
RxNorm normalized name: Loreal Preference Dark Auburn 4R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrace Vaginal Cream
Trial: NCT00236951
Drug: iron sucrose injection USP
RxNorm normalized name: iron sucrose Injection
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03492580
Drug: Anti-hyperglycemic Agents (AHA)
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention or treatment assignment imposed by this study. Participants received other selected AHA as a part of routine clinical practice. Other select AHAs includes: acarbose, bromocriptine, miglitol, nateglinide, repaglinide.
Trial: NCT03492580
Drug: Sulfonylureas (SU)
RxNorm normalized name: Sus scrofa skin
DrugBank: Sus scrofa skin (DB10606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention or treatment assignment imposed by this study. Participants received SU as a part of routine clinical practice. SUs includes: glipizide, glyburide, glimepiride, chlorpropamide, tolazamide, tolbutamide, acetohexamide
Trial: NCT02734420
Drug: Toluidine Blue O and PDT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial periapical and interproximal radiographs;Microbiological sample with otoscope curette to standardize volume of carious tissue;Application of Toluidine Blue O for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with sharp curette; No removal of carious tissue on pulp floor;non-cutting curette; Irradiation of dental tissue for one minute on a single point;Second microbiological sample of remaining dentin with curette;Clinical evaluation by inspection of texture of remaining dentin with exploratory probe; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE);Follow up;Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
Trial: NCT00003950
Drug: CPT-11
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02606682
Drug: NPT200-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of NPT200-11capsules, orally administered
Trial: NCT02606682
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of microcrystalline cellulose capsules, orally administered
Trial: NCT03763227
Drug: Carbonic Anhydrase Inhibitor (CAI) therapy
RxNorm normalized name: Carbonic anhydrase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbonic anhydrase therapy (Oral or Topical) in patients with retinal dystrophy and macular cysts
Trial: NCT00706069
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine at dose levels of 800 mg/m2, 950mg/m2, 1100mg/m2, 1250mg/m2 per os from day 1 to day 14 every 21 days
Trial: NCT02295280
Drug: Codeine
RxNorm normalized name: Codeine
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PO
Trial: NCT01070277
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo pills X2 /day for 2 days followed by~1 placebo Pill X2 / day for 7 days
Trial: NCT00065065
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pill that looks identical to rosiglitazone
Trial: NCT00064779
Drug: IL13-PE38QQR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00711074
Drug: AZD5672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose 200mg aqueous solution
Trial: NCT00194675
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel 7.5 g daily topical
Trial: NCT04618952
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01210287
Drug: nucleoside analog reverse transcriptase inhibitor
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets 100mg qd
Trial: NCT01722266
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to 1.2 mg of placebo: They will start placebo 0.6 mg sc once daily for one week and then increase to 1.2 mg once daily thereafter.~Patients randomized to 1.8 mg of placebo: They will start placebo 0.6 mg sc once daily for one week; increase to 1.2 mg sc once daily for second week and then to 1.8 mg sc once daily from third week onwards.
Trial: NCT04485429
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enoxaparin 1 mg/kg subcutaneously every 12 hours (if creatinine clearance greater than 40ml/min) or Unfractionated heparin dosed to target activated partial thromboplastin time (aPTT) between 1.5 - 2.0 times the normal value (if creatinine clearance less or equal to 40ml/min). The treatment period with full-dose heparin will be 7 days. After 7 days of full-dose heparin, patients will continue using prophylactic dose of heparin, according to the standard treatment routine.
Trial: NCT00676026
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.
Trial: NCT03262545
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical properties of placebos are consistent with apatinib
Trial: NCT05450575
Drug: Amosartan Q tablet
RxNorm normalized name: Chew Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine, Losartan, Rosuvastatin
Trial: NCT02405858
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisolone 5 mg will be concomitantly administered twice a day (10 mg/day) up to Cycle 26.
Trial: NCT01837485
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill was applied 3 times a day for 3 months
Trial: NCT01815203
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of one gelatin capsule containing 200-300 mg of caffeine with subsequent cognitive tasks and food test.
Trial: NCT01815203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo with subsequent cognitive tasks and food test.
Trial: NCT00911742
Drug: Zytram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Zytram 200 mg tablet as a single dose
Trial: NCT04128696
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is available as an intravenous infusion.
Trial: NCT04523831
Drug: Ivermectin and Doxycycline
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin 6 mg, 2 tab stat and Doxycycline 100 mg twice daily for 5 days
Trial: NCT04523831
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol, Vitamin D, Oxygen if indicated, Low molecular weight heparin, dexamethasone if indicated
Trial: NCT04166669
Drug: APX001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1 Day 1: APX001 500 mg IV BID over a 3-hour infusion; Day 18: APX001 500 mg IV BID over a 3-hour infusion. Cohort 2 Day 1: APX001 1000 mg IV BID over a 3-hour infusion; Day 24: APX001 1000 mg IV BID over a 3-hour infusion.
Trial: NCT02196506
Drug: Placebo + ADT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + ADT Placebo + FDA Approved Antidepressant (ADT)
Trial: NCT04502888
Drug: Drug: SL-172154
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
Trial: NCT02179658
Drug: OPT-80
RxNorm normalized name: Glau-Opt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT04221477
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching obinutuzumab will be administered by IV infusion at baseline and Weeks 0, 2, 24, 26, 50 and 52 and subsequently from Week 80 and every 6 months thereafter based on response.
Trial: NCT04221477
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.
Trial: NCT04458051
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Film-coated Tablet Route of administration: Oral
Trial: NCT01358877
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered as per the schedule specified in the respective arm.
Trial: NCT01358877
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin will be administered as per the schedule specified in the respective arm.
Trial: NCT00102492
Drug: GW679769
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01358877
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as per the schedule specified in the respective arm.
Trial: NCT01343628
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 NET SNP rs 11648486 CC and CT individuals will receive placebo and then after one week washout period, receive atomoxetine. Medications will be given as 2 capsules 1x day for 5 days; active atomoxetine groups will receive 40 mg for 3 days, followed by 80 or 120mg (.91-1.4 mg/kg) on days 4 and 5
Trial: NCT00420290
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks
Trial: NCT04472182
Drug: Fluoride varnish with xylitol coated calcium and phosphate
RxNorm normalized name: sodium fluoride / xylitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride varnish with xylitol coated calcium and phosphate
Trial: NCT01373476
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (4 placebos each time):4#, po, tid,24 weeks.
Trial: NCT00543855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: Two Donepezil hydrochloride Placebo tablets by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast.
Trial: NCT00002594
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00553748
Drug: F-18 FLT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One - 10 mci dose of F-18 FLT is administered IV over about 5 seconds prior to PET imaging. Each imaging dose contains no more than 6.1 micrograms of FLT.
Trial: NCT01246986
Drug: LY2157299
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01355523
Drug: Melatonin (N-acetyl-5-methoxytryptamine)
RxNorm normalized name: N-Acetyl-5-methoxytryptamine
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 mg oral melatonin daily 1 hour before bedtime
Trial: NCT01355523
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg oral placebo daily 1 hour before bedtime
Trial: NCT04072198
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m2 every 2 weeks for 8 cycles
Trial: NCT04072198
Drug: fluoruracil
RxNorm normalized name: 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
DrugBank: Doxifluridine (DB12947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3200mg/m2 every 2 weeks for 8 cycles
Trial: NCT01653470
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03462030
Drug: Baked non-fat cow's milk powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunotherapy with increasing quantities of baked milk.
Trial: NCT03462030
Drug: Placebo: Tapioca Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control.
Trial: NCT03876288
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigators would include follow up with: No treatment; temp gastric electrical stimulation (GES) only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
Trial: NCT03381196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 \[evening\], dosing will continue until the morning of Day 6).
Trial: NCT00071409
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mL, once daily, self-administered SC injection for 90 days
Trial: NCT01222715
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00562692
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion
Trial: NCT01860482
Drug: Newrabell® Tablet 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03836729
Drug: GSK3640254
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3640254 will be available as 100 mg capsule. Subjects will be administered GSK3640254 200 mg capsule QD via the oral route.
Trial: NCT04317963
Drug: Standard CDI treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard CDI treatment includes one or a combination of oral vancomycin, oral vancomycin taper and/or pulse, fidaxomicin, and fidaxomicin taper and/or pulse
Trial: NCT00084838
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00084838
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00084838
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00084838
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00084838
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00482287
Drug: MTR105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration, dose escalating (4 arms), single dose
Trial: NCT02097537
Drug: Methacholine Chloride (SK-1211)
RxNorm normalized name: Methacholine Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00882973
Drug: Genexol-PM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cremophor EL-free polymeric micelle of paclitaxel
Trial: NCT01612728
Drug: Women with Arthralgia
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00773383
Drug: RG1507
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv 9mg/kg weekly
Trial: NCT03339635
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to treatment with transdermal placebo gel once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
Trial: NCT04310748
Drug: Total Intravenous Anesthesia(TIVA)
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventilation of the patients was provided with a mixture of 40% oxygen and 60% air. Along with induction, propofol at a dose of 6-10 mg/kg/hour and remifentanil infusion at a dose of 0.3-0.4 mcg/kg/min were started for the maintenance of anesthesia. Drug concentrations were adjusted to maintain BIS values between 40-60 in the maintenance of anesthesia.~The MAP target was determined to be in the range of 50-65 mmHg. Blood was collected and stored to measure TAS, TOS, Catalase, Myeloperoxidase, Total Thiol, Native Thiol and Disulfide parameters before and after induction at 5,30,60 and 120 minutes. Hemodynamic data (HR, SBP, DBP, MAP, SpO2) and BIS values of the patients were recorded at 5-minute intervals. The extubation time was recorded. The surgical field opinion and satisfaction assessment were made by Boezaart Scoring and the survey presented to the surgeon, respectively. The patients were followed up for 30 minutes; numerical pain scores and nausea-vomiting scores were recorded
Trial: NCT04310748
Drug: Inhalation Anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventilation of the patients was provided with a mixture of 40% oxygen and 60% N2O. As soon as mechanical ventilation started, sevoflurane was opened at a concentration of 2-3% with a MAK value of 1.1-1.3. Drug concentrations were adjusted to maintain BIS values between 40-60 in the maintenance of anesthesia.~The MAP target was determined to be in the range of 50-65 mmHg. Blood was collected and stored to measure TAS, TOS, Catalase, Myeloperoxidase, Total Thiol, Native Thiol and Disulfide parameters before and after induction at 5,30,60 and 120 minutes. Hemodynamic data (HR, SBP, DBP, MAP, SpO2) and BIS values of the patients were recorded at 5-minute intervals. The extubation time was recorded. At the end of the surgery, the surgical field opinion and satisfaction assessment were made by Boezaart Scoring and the survey presented to the surgeon, respectively. The patients were followed up for 30 minutes; numerical pain scores and nausea-vomiting scores were recorded.
Trial: NCT03494205
Drug: institutional standard skin care Excipial-Hydrolotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The institutional standard skin care Excipial-Hydrolotion is available to all patients
Trial: NCT01456689
Drug: LGH447
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02117479
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tablets to be administered by mouth twice daily (BID)
Trial: NCT02900183
Drug: ARC-AAT Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RNA interference (RNAi)-based, liver-targeted therapeutic
Trial: NCT01052896
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Look-alike of gabapentin 300mg given po tid
Trial: NCT00497783
Drug: Lactoserum
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00685685
Drug: Lovastatin 40 mg tablets
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg tablet administered after an overnight fast of at least 10 hours
Trial: NCT00685685
Drug: Lovastatin (Mevacor®) 40 mg Tablets
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg tablet administered after an overnight fast of at least 10 hours
Trial: NCT02117479
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150 and 500 mg tablets to be administered by mouth twice daily (BID)
Trial: NCT04386915
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, and 500 mg. Based on the results of a single dose, select 1 to 3 doses from 100mg, 200mg, 300mg, and 400mg to conduct multiple dose studies.
Trial: NCT00647218
Drug: neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel 175 mg/m2 IV every 3 weeks x 3 cycles
Trial: NCT01275339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills is not tolerated, then the dose will be decreased back to 1 pill daily.
Trial: NCT01561027
Drug: CNV1014802
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in treatment arm.
Trial: NCT01561027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in treatment arm
Trial: NCT02981602
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04029116
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID (one day) every 4 weeks for a total of 6 dosing days
Trial: NCT00321061
Drug: VRC-HIVDNA016-00, VRC-HIVADV014-00
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00494598
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mcg intra-arterial one time bolus
Trial: NCT04190433
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO